 Among the pharmacological augmentation strategies, adjunctive antipsychotic medications enjoy the most empirical support as well as wide-scale use in clinical practice. Utilizing IMS Healths National Disease and Therapeutic Index NDTI for 12 months ending in November 2004, 4.2 of antipsychotic medication use is for anxiety and 1.3 specifically for OCD. Conversely, for OCD patients, antipsychotic medications account for 8.6 of drug use IMS Health NDTI MAT, 2004. Among pediatric patients, prescriptions of antipsychotics increased from 8.6 out of 1,000 U.S. children in 1995-1996 to 39.4 out of 1,000 children in 2001-2002 Cooper et al., 2006. Similarly, Medco, a private insurance company, noted that the rate of children 19 years and under covered by private insurance with at least one atypical prescription jumped 80 from 2001 to 2005 from 3.6 per 1,000 to 6.5 per 1,000 USA Today, extracted 522006. These rates parallel our own research, in which approximately 35 of adult patients on psychotropics were taking an antipsychotic in addition to their SRI. Thus, clearly there is a large sample of OCD patients that are being prescribed atypical antipsychotics to augment other treatments. 